

Pharmacy and Therapeutics Committee Meeting
March 2, 2004
Kellogg Hotel and Conference Center

Draft Minutes

Committee Members in Attendance

Giovannino Perri, M.D., acting chairman
Robert Coffey, Pharm.D.
Debera Eggleston, M.D.
Robert Ernst, M.D.
Jonathan Henry, M.D.
Max Robins, D.O.

Representatives of the Department of Community Health in Attendance

Michael Ezzo, Ph.D., Chief Deputy Director, Michigan Department of Community Health
George Baker, M.D., Chief Medical Consultant, Children's Special Health Care Services
Mary Sandusky, R.Ph., Pharmacy Consultant
Bradley Sprecher, Pharmacy Section Analyst

Representatives of First Health Services Corporation in Attendance

Annette Paul, R.Ph., Clinical Manager, Michigan Medicaid
Luenetta Jackson, Pharm.D., Michigan Account Manager

Public Audience

Approximately 90 persons attended.

Proceedings

- I. Dr. Giovannino Perri opened the meeting at 6:10 p.m.

- II. Dr. Perri mediated the Public Comment period. Speakers are listed in the order of presentation:
 - Michael Carella, M.D., Novo Nordisk: Novolog 70/30
 - Dr. Blake Casher, Forest Laboratories: Namenda
 - Arlene Price, Pharm.D., Abbot Laboratories: Tricor and Tarka
 - Dr. Linda Pullum, Alpharma: Kadian
 - Greg Warren and Dr. David Brill, Wyeth Pharmaceuticals: Altace
 - Todd Lacksonen and Aneel Mukir, TAP Pharmaceuticals: PrevacidNapraPAC
 - Dr. Doyle, BMS: Pravachol
 - Neal Huyc, GSK: Levitra
 - Rick Detloff, Pharm.D., Pfizer: Inspra
 - Tim Birner, Pharm.D., Sanofi Synthelabo: Uroxatral
 - Dr. Alan Goldberg, Merck: Zocor
 - Dan C. Dean, D.O.: Zocor, PA process
 -

- III. Approval of Minutes

The minutes of the December 2nd meeting were accepted as written.

- IV. New Drug Reviews

Dr. Perri noted that Abarelix and Plenaxis are the same product and are only available in an injectible form for administration under the supervision of a physician. This drug is administered in the clinic, office, or hospital setting and will not be reviewed by the P&T Committee.

Dr. Perri presented new products to the Committee for review. Background material was prepared by Annette Paul, R.Ph.

The Committee made the following recommendations:

- Inspra
Inspra should be added to the Michigan Pharmaceutical Product List (MPPL).
The Committee requested utilization data for this product for review at 3 and 6 months following the March 02, 2004 meeting.
- Levitra
Continue to require Prior Authorization until the class of impotence products can be reviewed (within 3 months of the March 02, 2004 meeting). This drug was rejected for inclusion on the MPPL.
- Namenda

Namenda should be added to the Preferred Drug List and MPPL without prior authorization.

- Uroxatral
Uroxatral should be added to the Michigan Pharmaceutical Product List without prior authorization.
- Zavesca
Zavesca should be added to the Michigan Pharmaceutical Product List without prior authorization.

V.&VI. Review of PDL Categories

Dr. Perri reminded P&T Committee members of the need to form workgroups for the annual PDL review.

Dr. Ernst emphasized the need to review the Lipotropics category.

The Committee concurred with the recommendation to divide the review of all PDL categories between the next 2 consecutive P&T Committee meetings (i.e. finishing the review at the September 14, 2004 meeting).

Adjournment

The meeting adjourned at 8:30 p.m.

Next Meeting is Tuesday, June 1st, 2004

6:00 P.M. – 9:00 P.M.

Kellogg Hotel and Conference Center

Respectfully submitted by Brad Sprecher